02302nas a2200265 4500000000100000000000100001008004100002260001500043653001700058653001300075653001900088653002100107653001500128100001700143700001800160700001700178700001800195700001600213700001500229700001700244245011700261856005500378520158900433022001402022 2025 d c2025-12-2910aCell biology10aDiseases10aDrug Discovery10amedical research10aStem cells1 aHae-Ran Park1 aYeongkag Kwon1 aHyun Jung Ji1 aSun-Young Kim1 aMin-Kyu Kim1 aKi Bum Ahn1 aHo Seong Seo00aA human lung organoid platform for studying radiation-induced pulmonary fibrosis and antifibrotic drug screening uhttps://www.nature.com/articles/s41598-025-31582-13 aRadiation-induced pulmonary injury and fibrosis (RIPI/RIPF) is a major complication following thoracic radiotherapy, characterized by persistent inflammation and excessive extracellular matrix deposition leading to irreversible lung disease. The development of antifibrotic drugs has been limited by the lack of physiologically relevant in vitro models that mimic the complex lung microenvironment. In this study, we established a human embryonic stem cells-derived human lung organoids (hLOs) model, comprising major epithelial cell types, including AT1, AT2, goblet, basal, club, and ciliated cells. Following repeated irradiation, hLOs exhibited key features of RIPF, including impaired proliferation, epithelial barrier disruption, epithelial-mesenchymal transition, upregulation of profibrotic cytokines, and extensive collagen deposition. Single-cell RNA sequencing revealed a marked reduction in proliferative AT2 cells and shifts in epithelial subpopulations, mimicking cellular dynamics observed in vivo. Importantly, Pirfenidone, an antifibrotic drug, significantly reduced the expression of TGF-β, α-SMA, and COL1A2 in irradiated hLOs. These findings demonstrate that our hESC-derived hLO model recapitulates key molecular and structural features of RIPF and offers a human-relevant, scalable platform for mechanistic studies and antifibrotic drug screening. This organoid system provides a time-efficient alternative to conventional animal models, enabling fibrosis-like responses, and may serve as a valuable tool for advancing therapeutic strategies against RIPI/RIPF. a2045-2322